Holistic View of ALK TKI Resistance in ALK-Positive Anaplastic Large Cell Lymphoma

Anaplastic lymphoma kinase (ALK) is a receptor tyrosine kinase expressed at early stages of normal development and in various cancers including ALK-positive anaplastic large cell lymphoma (ALK+ ALCL), in which it is the main therapeutic target. ALK tyrosine kinase inhibitors (ALK TKIs) have greatly...

ver descrição completa

Detalhes bibliográficos

Principais autores:	Yuan Wang, Jing He, Manyu Xu, Qingfeng Xue, Cindy Zhu, Juan Liu, Yaping Zhang, Wenyu Shi
Formato:	Artigo
Idioma:	Inglês
Publicado em:	Frontiers Media S.A. 2022-02-01
coleção:	Frontiers in Oncology
Assuntos:	ALCL ALK ALK-TKI lymphoma drug resistance therapy
Acesso em linha:	https://www.frontiersin.org/articles/10.3389/fonc.2022.815654/full
Tags:	Adicionar Tag Sem tags, seja o primeiro a adicionar uma tag!